The pharmaceutical company reported third-quarter earnings and sales that beat analysts’ expectations, boosted by ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

GSK, Sanofi, CSL nab $72M in BARDA funding to boost bird flu vaccine supply In Merck’s infant RSV study, clesrovimab managed to cut RSV-related hospitalizations and RSV-related lower respiratory ...

its RSV antibody for infants. Announcing earnings Friday, the French pharmaceutical company said Beyfortus sales were 645 million euros, or about $700 million. Overall, Sanofi’s vaccines unit ...

Sanofi has added to its vaccine pipeline with an agreement ... It will highlight vaccines for pneumococcal disease, meningitis, respiratory syncytial virus (RSV), influenza, and chlamydia.

Growth at the vaccines business was driven in part by ... Merck & Co. also has a rival monoclonal antibody shot in development for RSV. Sanofi’s chief financial officer, François-Xavier Roger ...

Beyfortus (RSV) sales were ... soft vaccination rate. 2024 vaccine sales are expected to grow high single-digit compared to the earlier mid-single-digit range. Sanofi forecasts Beyfortus sales ...

boosted by earlier-than-anticipated deliveries of flu and respiratory syncytial virus vaccines and growing demand for blockbuster anti-inflammatory drug Dupixent. Sanofi’s third-quarter results ...

Sales of meningitis, travel and other endemic vaccines rose 13.1% year over year in the quarter. Sanofi and partner AstraZeneca’s AZN RSV antibody Beyfortus (nirsevimab) recorded sales of €645 ...

Sanofi reported third-quarter earnings and sales that beat analysts' expectations, boosted by earlier-than-anticipated deliveries of flu and respiratory syncytial virus vaccines and growing demand ...